Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights

SG&A Expenses: Novartis vs. Gilead - A Decade of Insights

__timestampGilead Sciences, Inc.Novartis AG
Wednesday, January 1, 2014298300000014993000000
Thursday, January 1, 2015342600000014247000000
Friday, January 1, 2016339800000014192000000
Sunday, January 1, 2017387800000014997000000
Monday, January 1, 2018405600000016471000000
Tuesday, January 1, 2019438100000014369000000
Wednesday, January 1, 2020515100000014197000000
Friday, January 1, 2021524600000014886000000
Saturday, January 1, 2022567300000014253000000
Sunday, January 1, 2023609000000012489000000
Monday, January 1, 2024609100000012566000000
Loading chart...

In pursuit of knowledge

SG&A Expenses: A Tale of Two Giants

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Novartis AG and Gilead Sciences, Inc. from 2014 to 2023. Over this period, Novartis consistently outspent Gilead, with its SG&A expenses peaking at approximately $16.5 billion in 2018. In contrast, Gilead's expenses showed a steady upward trend, culminating in a 104% increase from 2014 to 2023. This divergence highlights Novartis's aggressive market strategies and Gilead's gradual expansion. Such insights are invaluable for investors and industry analysts seeking to understand the financial health and strategic priorities of these pharmaceutical titans.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025